Trial Search Results

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

The purpose of this study is to determine the safety and tolerability of PF-03084014 in patients with metastatic or locally recurrent / advanced triple-negative breast cancer (mTNBC). PF-03084014 is a selective gamma secretase (GS) inhibitor with potential antitumor activity.

In addition we hope to learn about the tumor killing effect that PR-03084014 may have when taken in combination with docetaxel. We would also like to see how long after treatment PF-03084014 remains in the body, and see what PF-03084014 taken in combination with docetaxel does to the body, for example, how it stimulates the body to fight cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:



  • Drug: PF-03084014
  • Drug: PF-03084014
  • Drug: PF-03084014
  • Drug: Docetaxel
  • Drug: Docetaxel


Phase 1


Inclusion Criteria:

   - Diagnosis of breast cancer with evidence of a) metastatic or b) locally
   recurrent/advanced disease.

Exclusion Criteria:

   - Prior treatment with a gamma secretase inhibitors or other Notch signaling inhibitors.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting